About 9 results found for searched term "K 308" (0.121 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1758 | Foretinib | c-Met |
| GSK089; EXEL-2880; XL880; GSK1363089 | ||
| Foretinib (XL880, GSK1363089) is a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 (VEGFR2) with IC50 value of 0.4 nM for c-MET. | ||
| M10842 | KAG-308 | Prostaglandin Receptor |
| KAG-308 is an effective, selective, orallyable EP4 receptor (a subtype of prostaglandin E2 receptor) agonist that inhibits colitis, promotes tissue mucosal healing, and effectively inhibits the production of TNF-α. KAG-308 for human EP4 receptors Ki value and EC50 The values were 2.57 nM and 17 nM, respectively, which were more selective than EP1, EP2, EP3, and IP receptors. | ||
| M43139 | K 308 | Others |
| K 308 is a non-steroid antiinflammatory agent. | ||
| M1984 | PF-04691502 | PI3K |
| PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. | ||
| M8594 | BRD3308 | HDAC |
| BRD3308 is a highly selective HDAC3 inhibitor with an IC50 of 54 nM. BRD3308 is 23 times more selective to HDAC3 than HDAC1 (IC50:1.26 μM) or HDAC2 (IC50:1.34 μM). BRD3308 inhibits pancreatic β cell apoptosis induced by inflammatory cytokines or glucolipid toxic stress and increases functional insulin release. BRD3308 also activates HIV-1 transcription and disrupts HIV-1 latency. | ||
| M10382 | PROTAC SGK3 degrader-1 | PROTAC |
| SGK3-PROTAC1 | ||
| PROTAC SGK3 degrader-1 (SGK3-PROTAC1) is a potent SGK3 degrader, it is a PROTAC conjugate of the 308-R SGK inhibitor with the VH032 VHL binding ligand, targeting SGK3. | ||
| M24956 | Cendakimab | IL Receptor/Related |
| RPC 4046; ABT 308; CC-93538 | ||
| Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. | ||
| M29316 | JNJ-55308942 | P2 Receptor |
| JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC50=10 nM, Ki=7.1 nM; rP2X7: IC50=15 nM, Ki=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain. | ||
| M55693 | HU-308 | Cannabinoid |
| HU308 | ||
| HU-308 is a potent, selective agonist of the cannabinoid receptor CB2, with Ki values of 22.7nM and >10 mM for CB2 and CB1, respectively. HU-308 has anti-inflammatory and neuroprotective properties. HU-308 reduces liver damage in a hepatic ischemia/reperfusion injury model. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
